Regeneron Pharmaceuticals Earnings: Here’s Why Investors are Selling Shares Now

  Google+ | + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) delivered a profit and beat Wall Street’s expectations, BUT came up short on beating the revenue expectation. The revenue miss is a negative sign to shareholders seeking high growth out of the company. Shares are down 4.51%.

Regeneron Pharmaceuticals, Inc. Earnings Cheat Sheet

Results: Adjusted Earnings Per Share increased 147.14% to $1.73 in the quarter versus EPS of $0.70 in the year-earlier quarter.

Revenue: Rose 50.33% to $457.6 million from the year-earlier quarter.

Actual vs. Wall St. Expectations: Regeneron Pharmaceuticals, Inc. reported adjusted EPS income of $1.73 per share. By that measure, the company beat the mean analyst estimate of $0.88. It missed the average revenue estimate of $473.23 million.

Quoting Management: “We are pleased with these positive data in another potentially important indication for EYLEA,” said George D. Yancopoulos, M.D., Ph. D., Chief Scientific Officer of Regeneron and President of Regeneron Laboratories. “Diabetes is a growing disease worldwide and DME is a major cause of vision loss in people with diabetic retinopathy. We hope to be able to offer a new treatment option for patients suffering from this potentially blinding retinal disease.”

Key Stats (on next page)…

More Articles About:

To contact the reporter on this story: To contact the editor responsible for this story:

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business